NCT00749632已完成2 期
An Open-Label, Dose Escalating Study to Evaluate the Safety of Intravaginal Oxybutynin in Subjects With Urge Urinary Incontinence
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 45
- 试验地点
- 2
- 主要终点
- Number of micturations and incontinence episodes.
研究概览
简要总结
The purpose of this study is to determine the safety of three doses of oxybutynin for the treatment of urge urinary incontinence.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Females 18 to 75 years of age
- •Has reported symptoms of urge urinary incontinence/overactive bladder
排除标准
- •Is pregnant or lactating
- •Has had lower urinary tract surgery within 6 months prior to Screening
- •Has a history of urinary retention
研究组 & 干预措施
1
Active Comparator
干预措施: oxybutynin (Drug)
2
Active Comparator
干预措施: oxybutynin (Drug)
3
Active Comparator
干预措施: oxybutynin (Drug)
结局指标
主要结局
Number of micturations and incontinence episodes.
时间窗: Two weeks pretreatment and three weeks on treatment
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
A Study to Evaluate the Safety and Efficacy of OROS® Oxybutynin Chloride for the Treatment of Urge Urinary IncontinenceUrinary IncontinenceNCT00269724Alza Corporation, DE, USA250
已完成
1 期
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.Brain MetastasesMalignant GliomaBreast CancerLung CancerMelanomaNCT01386580BBB-Therapeutics B.V.84
尚未招募
1 期
Study of NM8074 in Adult C3 Glomerulopathy PatientsC3 GlomerulopathyNCT05647811NovelMed Therapeutics18
已完成
3 期
A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic PsoriasisPsoriasisNCT03022045AbbVie18
已完成
1 期
Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid TumorsNeoplasmsNCT01362374Genentech, Inc.122